PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

By Justin S. Smith, I. Tachibana, S. Passe, B. Huntley, T. Borell, N. Iturria, Judith R. O'Fallon, P. Schaefer, B. Scheithauer, C. James and 2 more. Journal of the National Cancer Institute, 2001

617 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/9b4479a0e9548bba2ffca56f3a6a888ba3e0a805

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “EGFR activity is enhanced by upregulation of EGFR protein expression, inhibition/deletion of downstream pathway inhibitors, constitutively active EGFR (EGFRvIII), and EGFR amplification (114, 115).”
Long-term survival with glioblastoma multiforme. (2007, background): “, 2005), or even reported an association with better prognosis (Houillier et al., 2006; Smith et al., 2001).”
Brain Tumor Epidemiology: Consensus from the Brain Tumor Epidemiology Consortium (BTEC) (2008, background): “There is a very strong and consistent, inverse correlation between age and survival for the various histologic subtypes of glioma (www.cbtrus.org accessed March 1, 2008), and younger patients benefit more from radiation therapy than older patients.164 In addition, combined loss of chromosomes 1p and”
Genetic Pathways to Glioblastoma (2004, background): “of glioblastoma patients (18, 25, 46), and this was confirmed in the”
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (2006, background): “Loss of chromosome (chr) 10q is a more frequent occurrence in GBM than AA and has been associated with short GBM survival (Balesaria et al., 1999; Schmidt et al., 2002; Smith et al., 2001).”
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. (2005, background): “In several hospitalbased studies, PTEN mutations were not associated with prognosis of glioblastoma patients (28, 34, 35), and this was confirmed at the population level (8).”